Bausch Health Companies Inc. Operating Lease Cost
Bausch Health Companies Inc. (BHC) reported Operating Lease Cost of $83.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-19
- Bausch Health Companies Inc. operating lease, cost for the quarter ending 2019-12-31 was $15.00M.
- Bausch Health Companies Inc. operating lease, cost for the quarter ending 2019-09-30 was $15.00M.
- Bausch Health Companies Inc. operating lease, cost for the quarter ending 2019-06-30 was $16.00M.
- Bausch Health Companies Inc. operating lease, cost for the quarter ending 2019-03-31 was $16.00M.
- Bausch Health Companies Inc. operating lease, cost for fiscal 2025 was $83.00M, a 12.16% increase from fiscal 2024.
- Bausch Health Companies Inc. operating lease, cost for fiscal 2024 was $74.00M, a 13.85% increase from fiscal 2023.
- Bausch Health Companies Inc. operating lease, cost for fiscal 2023 was $65.00M, a 4.84% increase from fiscal 2022.
- Bausch Health Companies Inc. operating lease, cost for fiscal 2022 was $62.00M, a 7.46% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $83.00M 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $74.00M 10-K · filed 2026-02-19 | |||
| 2023-12-31 | $65.00M 10-K · filed 2026-02-19 | |||
| 2022-12-31 | $62.00M 10-K · filed 2025-02-20 | |||
| 2021-12-31 | $67.00M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $65.00M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $15.00M derived: 8-K 12 month − 10-Q 9 month · filed 2022-05-11 | $30.00M derived: sum of 2 quarters · filed 2022-05-11 | $46.00M derived: sum of 3 quarters · filed 2022-05-11 | $62.00M 8-K · filed 2022-05-11 |
| 2019-09-30 | $15.00M 10-Q · filed 2019-11-04 | $31.00M derived: sum of 2 quarters · filed 2019-11-04 | $47.00M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $16.00M 10-Q · filed 2019-08-06 | $32.00M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $16.00M 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |